Tue, May 17
|Online Event, Webinar via Zoom
Implementation of HIV Management Guidelines: TLD vs TEE
Themes: * Stable adults patient * TB/HIV co-infection * Pregnancy * Paediatrics * Transition to DTG: 1st line vs 2nd line * Side Effects * Drug-Drug interactions
Time & Location
May 17, 2022, 6:00 PM – 8:00 PM GMT+2
Online Event, Webinar via Zoom
About the event
The 2020 South African HIV Management Guidelines recommend the use of the dolutegravir-based regimens as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. Integrase inhibitors such as dolutegravir have many advantages over their non-nucleoside reverse-transcriptase inhibitor (NNTRI) counterparts such as efavirenz—better tolerability and fewer side-effects, better efficacy, low cost, and a high genetic barrier to resistance. However controversies associated with dolutegravir may have hindered its uptake. This Webinar aims to clarify any conflicting information, share evidence that will improve the confidence of healthcare providers to initiate ARV regimens as per national clinical guidelines, improve communication and client counselling.
Date: 17 May 2022
Time: 18:00 - 20:00
Topic: Implementation of HIV Management Guidelines: TLD vs TEE
Themes:
- Stable adults patient
- TB/HIV co-infection
- Pregnancy
- Paediatrics
- Transition to DTG: 1st line vs 2nd line
- Side Effects
- Drug-Drug interactions
Host: Dr Lesego Mawela
(N.B) After registering, you will receive a confirmation email containing information about joining the webinar.
For enquiries:
Email: info@clinicalcareplatform.com
Call/WhatsApp: 064 543 3928
Website: www.clinicalcareplatform.com